How to take ARCALYST

ARCALYST is a once-weekly, self-administered subcutaneous (under the skin) injection.

Arcalyst Bottle

You will receive your first injection with the help of a healthcare provider in the doctor’s office, or with the support of an ARCALYST Clinical Educator. You will then self-administer a once-weekly injection.

Do not try to give yourself ARCALYST injections until you are sure that you understand how to prepare and inject your dose.

Step-by-step administration

In addition to what you have learned from your healthcare provider or ARCALYST Clinical Educator, the resources below can help you better understand how to prepare and inject ARCALYST.

  • Step-By-Step Injection Graphic

    Step-by-step injection video

  • How to use  Arcalyst guide

    Step-by-step Instruction manual

  • Do you have injection-related questions?

    If you have injection-related questions, the Kiniksa OneConnect team can assist.

    The team can also set up one-on-one injection training with an ARCALYST Clinical Educator.

    Frequently asked questions about how to take ARCALYST

    ARCALYST is a prescription medicine called an interleukin-1 (IL-1) blocker.

    • ARCALYST is used to treat adults and children 12 years and older with Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS)
    • ARCALYST is used to maintain control of symptoms of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and children weighing at least 22 pounds (10 kg)
    • ARCALYST is used to treat Recurrent Pericarditis (RP) and reduce the risk of recurrence in adults and children 12 years and older

    It is not known if ARCALYST is safe and effective in children under 12 years of age. It is not known if ARCALYST is safe and effective in children with DIRA weighing less than 22 pounds (10 kg).

    Your Kiniksa OneConnect Patient Access Lead will help you coordinate the delivery of your medication and supplies.

    The Kiniksa OneConnect program is made up of a team of dedicated Patient Access Leads who provide personalized one-on-one support at each step of your treatment journey with ARCALYST. You can find services to help you with starting treatment, financial assistance, and treatment support. You can contact a Kiniksa OneConnect team member at 1-833-KINIKSA (1-833-546-4572) Monday-Friday (8 AM – 8 PM ET).

    ARCALYST Clinical Educators are qualified personnel who can assist you with virtual training to help you better understand the self-injection process.

    Take ARCALYST exactly as prescribed by your healthcare provider.

    ARCALYST is given by injection under the skin (subcutaneous injection) 1 time each week. A healthcare provider will tell you how much ARCALYST to take. The Kiniksa OneConnect program can work with you to set up one-on-one injection training sessions with an ARCALYST Clinical Educator, so you are familiar with the administration process. Do not try to give yourself ARCALYST injections until you are sure that you understand how to prepare and inject your dose. Call your healthcare provider, pharmacist, or your Kiniksa OneConnect Patient Access Lead at 1-833-KINIKSA (1-833-546-4572) if you have any questions.

    Other resources include the Step-by-Step Injection video and the Step-by-Step Injection manual.

    ARCALYST is a once-weekly, self-administered medication given by injection under the skin (subcutaneous).

    Keep ARCALYST in the carton it comes in to protect it from light. Store ARCALYST in the refrigerator between 36 °F and 46 °F (2 °C and 8 °C). Refrigerated ARCALYST can be used until the expiration date printed on the vial and carton. ARCALYST may be kept at room temperature after mixing with sterile water for injection and should be used within 3 hours of mixing.

    Keep ARCALYST away from light, and keep ARCALYST, injection supplies, and all other medicines out of the reach of children.

    If you miss a dose, you should speak with your healthcare provider. For more information, please see the full Prescribing Information.

    It is normal for the powder in the ARCALYST vial to appear as a solid clump or disc. If this is observed, continue following the steps related to the reconstitution of ARCALYST as outlined in the Instructions for Use. You may need to shake the vial back and forth for an extended period of time (repeat step 25 in the Instructions for Use) until the powder has completely dissolved and the solution is clear.

    ARCALYST should be stored in the refrigerator between 36 °F and 46 °F (2 °C and 8 °C) until it is time to prepare the product for your dose.

    If you receive your ARCALYST and the product feels warm to the touch or the temperature monitor inside the shipping container has been activated, please contact your Patient Access Lead who can provide guidance on the use of the product.

    Talk to your healthcare provider if you experience any side effects that bother you or that do not go away. Please report side effects by contacting Kiniksa Pharmaceuticals toll-free at 1-833-546-4572, Option 3, or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    ARCALYST can cause serious side effects, including:
    • Risk of Cancer. Medicines that affect the immune system may increase the risk of getting cancer.
    • Allergic Reaction. Stop taking or giving ARCALYST and call the healthcare provider or get emergency care right away if you get any of the following symptoms of an allergic reaction while taking ARCALYST:
      • Rash
      • Swollen face
      • Trouble breathing
    • Changes in your blood cholesterol and triglycerides (lipids). Your healthcare provider will do blood tests to check for these changes.
    • In people with CAPS and RP, the most common side effects of ARCALYST include:
      • Injection-site reactions including: pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site.
      • Upper respiratory tract infections
      • Joint and muscle aches in RP
    • In people with DIRA, the most common side effects of ARCALYST include:
      • Upper respiratory tract infections
      • Rash
      • Ear infection
      • Sore throat
      • Runny nose

    These are not all the possible side effects of ARCALYST. Tell your healthcare provider if you have any side effect that bothers you or does not go away. For more information, ask your healthcare provider or pharmacist.

    ARCALYST is a prescription medicine called an interleukin-1 (IL-1) blocker.

    • ARCALYST is used to treat adults and children 12 years and older with Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS)
    • ARCALYST is used to maintain control of symptoms of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and children weighing at least 22 pounds (10 kg)
    • ARCALYST is used to treat Recurrent Pericarditis (RP) and reduce the risk of recurrence in adults and children 12 years and older

    It is not known if ARCALYST is safe and effective in children under 12 years of age. It is not known if ARCALYST is safe and effective in children with DIRA weighing less than 22 pounds (10 kg).

    Your Kiniksa OneConnect Patient Access Lead will help you coordinate the delivery of your medication and supplies.

    The Kiniksa OneConnect program is made up of a team of dedicated Patient Access Leads who provide personalized one-on-one support at each step of your treatment journey with ARCALYST. You can find services to help you with starting treatment, financial assistance, and treatment support. You can contact a Kiniksa OneConnect team member at 1-833-KINIKSA (1-833-546-4572) Monday-Friday (8 AM – 8 PM ET).

    ARCALYST Clinical Educators are qualified personnel who can assist you with virtual training to help you better understand the self-injection process.

    Take ARCALYST exactly as prescribed by your healthcare provider.

    ARCALYST is given by injection under the skin (subcutaneous injection) 1 time each week. A healthcare provider will tell you how much ARCALYST to take. The Kiniksa OneConnect program can work with you to set up one-on-one injection training sessions with an ARCALYST Clinical Educator, so you are familiar with the administration process. Do not try to give yourself ARCALYST injections until you are sure that you understand how to prepare and inject your dose. Call your healthcare provider, pharmacist, or your Kiniksa OneConnect Patient Access Lead at 1-833-KINIKSA (1-833-546-4572) if you have any questions.

    Other resources include the Step-by-Step Injection video and the Step-by-Step Injection manual.

    ARCALYST is a once-weekly, self-administered medication given by injection under the skin (subcutaneous).

    Keep ARCALYST in the carton it comes in to protect it from light. Store ARCALYST in the refrigerator between 36 °F and 46 °F (2 °C and 8 °C). Refrigerated ARCALYST can be used until the expiration date printed on the vial and carton. ARCALYST may be kept at room temperature after mixing with sterile water for injection and should be used within 3 hours of mixing.

    Keep ARCALYST away from light, and keep ARCALYST, injection supplies, and all other medicines out of the reach of children.

    If you miss a dose, you should speak with your healthcare provider. For more information, please see the full Prescribing Information.

    It is normal for the powder in the ARCALYST vial to appear as a solid clump or disc. If this is observed, continue following the steps related to the reconstitution of ARCALYST as outlined in the Instructions for Use. You may need to shake the vial back and forth for an extended period of time (repeat step 25 in the Instructions for Use) until the powder has completely dissolved and the solution is clear.

    ARCALYST should be stored in the refrigerator between 36 °F and 46 °F (2 °C and 8 °C) until it is time to prepare the product for your dose.

    If you receive your ARCALYST and the product feels warm to the touch or the temperature monitor inside the shipping container has been activated, please contact your Patient Access Lead who can provide guidance on the use of the product.

    Talk to your healthcare provider if you experience any side effects that bother you or that do not go away. Please report side effects by contacting Kiniksa Pharmaceuticals toll-free at 1-833-546-4572, Option 3, or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    ARCALYST can cause serious side effects, including:
    • Risk of Cancer. Medicines that affect the immune system may increase the risk of getting cancer.
    • Allergic Reaction. Stop taking or giving ARCALYST and call the healthcare provider or get emergency care right away if you get any of the following symptoms of an allergic reaction while taking ARCALYST:
      • Rash
      • Swollen face
      • Trouble breathing
    • Changes in your blood cholesterol and triglycerides (lipids). Your healthcare provider will do blood tests to check for these changes.
    • In people with CAPS and RP, the most common side effects of ARCALYST include:
      • Injection-site reactions including: pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site.
      • Upper respiratory tract infections
      • Joint and muscle aches in RP
    • In people with DIRA, the most common side effects of ARCALYST include:
      • Upper respiratory tract infections
      • Rash
      • Ear infection
      • Sore throat
      • Runny nose

    These are not all the possible side effects of ARCALYST. Tell your healthcare provider if you have any side effect that bothers you or does not go away. For more information, ask your healthcare provider or pharmacist.

    Make sure to keep taking ARCALYST as instructed by your healthcare provider.

    ARCALYST not only treats recurrent pericarditis flares as they happen, it also effectively reduces the risk of having more flares in the future. So even if your symptoms are under control, make sure to continue taking ARCALYST as your healthcare provider has instructed to help keep it that way.